hydroxyethyl starch
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00199706 | Apr 2002 → Oct 2004 | subarachnoid hemorrhage | Oslo University Hospital | Completed | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT02502773 | Feb 2016 → Jul 2018 | — | University Hospital, Clermont-Ferrand | Completed | Missed primary |
| Phase 3 | NCT00935168 | Dec 2009 → Apr 2012 | — | The George Institute | Completed | Missed primary |
| Phase 44 trials | ||||||
| Phase 4 | NCT07410988 | Jun 2026 → Jun 2029 expected | — | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02009033 | Sep 2011 → Apr 2013 | blood coagulation disease | K. C. Rasmussen | Completed | No outcome recorded |
| Phase 4 | NCT00542516 | Sep 2006 → Nov 2008 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00308126 | Jun 2005 → Sep 2006 | — | Fresenius Kabi | Completed | No outcome recorded |
| Phase not applicable13 trials · 2 missed | ||||||
| — | NCT05712018 | Oct 2023 → Jan 2024 | — | General Hospital of Ningxia Medical University | Completed | No outcome recorded |
| — | NCT05475990 | Jan → Mar 2023 | — | General Hospital of Ningxia Medical University | Completed | No outcome recorded |
| — | NCT03306914 | Oct 2017 → Feb 2019 | — | Cairo University | Completed | No outcome recorded |
| — | NCT02882074 | Jun 2016 → Feb 2020 | — | The Cleveland Clinic | Completed | Missed primary |
| — | NCT03107598 | Mar → Sep 2016 | hypotensive disorder | University Hospital, Mahdia | Terminated | No outcome recorded |
| — | NCT02361736 | Mar → Dec 2015 | — | Yuanyuan Zhang | Completed | No outcome recorded |
| — | NCT02208570 | Jul 2014 → Dec 2016 | hypotensive disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT02034682 | Jan → Aug 2014 | — | University Hospital, Ghent | Completed | No outcome recorded |
| — | NCT02306213 | Jan 2011 → Apr 2013 | — | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT01195883 | Nov 2010 → Nov 2016 | — | The Cleveland Clinic | Completed | Missed primary |
| — | NCT02337010 | Oct 2010 → Sep 2013 | — | Domonkos Trásy | Completed | No outcome recorded |
| — | NCT00518544 | Jul 2007 → ? | — | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00255957 | Oct 2005 → Mar 2006 | — | Nizam's Institute of Medical Sciences University, India | Completed | No outcome recorded |
| Comparator or background therapy24 trials | ||||||
| Phase 0 | NCT05505708 Comparator | Dec 2022 → Jan 2023 | pulmonary edema | Kasr El Aini Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT01530490 Background | Aug 2007 → Aug 2008 | ovarian disorder | Hospital de Cruces | Completed | Missed primary |
| Phase 2 | NCT02622126 Comparator | Jan → Jul 2016 | blood coagulation disease | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT01511120 Comparator | Nov 2011 → Dec 2013 | coronary artery disorder | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01028339 Background | Jul 2008 → Jun 2012 | traumatic brain injury | Central Directorate of the Army Health Service | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01120730 Comparator | Apr 1997 → Sep 1998 | kidney failure | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT02393196 Comparator | Mar 2015 → Jan 2016 | hypotensive disorder | Sifa University | Unknown | No outcome recorded |
| Phase 4 | NCT02064075 Comparator | Feb → Oct 2013 | subarachnoid hemorrhage | University of Debrecen | Completed | No outcome recorded |
| Phase 4 | NCT01486563 Comparator | Jan 2012 → Jun 2013 | prostate cancer | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 4 | NCT01486576 Comparator | Jan 2012 → Mar 2013 | osteoarthritis | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 4 | NCT01486550 Comparator | Dec 2011 → Sep 2014 | kidney cancer | Regional Hospital Holstebro | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01348659 Comparator | May 2011 → May 2012 | — | Kati Järvelä | Completed | No outcome recorded |
| Phase 4 | NCT01741610 Comparator | Oct 2008 → Aug 2011 | — | Cukurova University | Completed | No outcome recorded |
| Phase 4 | NCT01654653 Comparator | Jul 2008 → Mar 2009 | coronary artery disorder | Innogene Kalbiotech Pte. Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00549419 Comparator | Oct 2007 → Jan 2009 | — | Klinikum Ludwigshafen | Completed | No outcome recorded |
| Phase 4 | NCT00517127 Comparator | Sep 2006 → Dec 2016 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01174719 Comparator | Mar 2006 → Feb 2010 | coronary artery disorder, heart valve disorder | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00273728 Comparator | May 2005 → Jun 2010 | infectious disease with sepsis | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT06664320 Comparator | Oct 2024 → Mar 2025 overdue | mitral valve insufficiency, mitral valve stenosis, tricuspid valve insufficiency | Konkuk University Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT03048162 Comparator | Feb → May 2017 | — | Tokat Gaziosmanpasa University | Completed | No outcome recorded |
| — | NCT02502448 Comparator | Jan → Jun 2016 | mitral valve insufficiency, mitral valve stenosis, tricuspid valve insufficiency | Konkuk University Medical Center | Completed | No outcome recorded |
| — | NCT02599155 Comparator | Nov 2015 → Feb 2016 | acute kidney injury | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT00973414 Comparator | Mar → Sep 2009 | — | Nanjing Medical University | Completed | No outcome recorded |
| — | NCT00973791 Comparator | Oct 2008 → May 2009 | — | Nanjing Medical University | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 46 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hydroxyethyl starch | “The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES, voluven) administered by gravity at a wide-open rate over a period of 15-30min before...” NCT03107598 ↗44“Patients undergoing moderate- to high-risk open abdominal surgery were randomly assigned to goal-directed lactated Ringer's solution (n = 58) or a hydroxyethyl starch 6%...” PMID 32825817 ↗ Aug 2020 “This trial aims to compare two intraoperative fluids, namely hydroxyethyl starch (HES) and balanced crystalloids in terms of major adverse kidney events after cardiac surgery.” NCT07410988 ↗ “an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.” NCT01195883 ↗ “In the starch group, 6% hydroxyethyl starch 130/0.4 (Volulyte® ) was used as the primary fluid for volume resuscitation but was limited to 30 ml.kg-1 .” PMID 29150842 ↗ Nov 2017 “250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.” NCT02337010 ↗ “hyperoncotic hydroxyethyl starch (HES) 200/0.5 (10%) administered in combination with crystalloids within the first 24 hours after injury” PMID 20584291 ↗ Jun 2010 “Hydroxyethyl starch (HES) solutions are widely used in surgical patients as a component of goal-directed fluid optimization strategies” PMID 26690683 ↗ Dec 2015 “rapid crystalloid (Lactated Ringer's solution) or colloid (hydroxyethyl starch; HES) cohydration with a second intravenous access line” NCT01741610 ↗ “Infusion of hydroxyethyl starch (HES) impairs coagulation and, in O blood type, apparent coagulopathy can develop after HES infusion.” NCT00518544 ↗ “The two fluids being compared are 0.9% sodium chloride (saline) and 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride,(starch).” NCT00935168 ↗ |
| Known as | 6% HES | “The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES, voluven) administered by gravity at a wide-open rate over a period of 15-30min before...” NCT03107598 ↗ |
| Known as | HES | “250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.” NCT02337010 ↗8“hyperoncotic hydroxyethyl starch (HES) 200/0.5 (10%) administered in combination with crystalloids within the first 24 hours after injury” PMID 20584291 ↗ Jun 2010 “Hydroxyethyl starch (HES) solutions are widely used in surgical patients as a component of goal-directed fluid optimization strategies” PMID 26690683 ↗ Dec 2015 “rapid crystalloid (Lactated Ringer's solution) or colloid (hydroxyethyl starch; HES) cohydration with a second intravenous access line” NCT01741610 ↗ “Infusion of hydroxyethyl starch (HES) impairs coagulation and, in O blood type, apparent coagulopathy can develop after HES infusion.” NCT00518544 ↗ “fluid boluses of hydroxyethyl starch (HES) or lactated Ringer's (LR) solution guided by oesophageal Doppler.” PMID 31627889 ↗ Oct 2019 “This study aims to compare hemodynamic effects and fluid balance of HSL with 6% Hydroxy Ethyl Starch (HES).” NCT01654653 ↗ “6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery” NCT02361736 ↗ “Albumin 5%, Hydroxyethylstarch 130/0.4 (HES) and Ringer-Lactate (RL)” NCT01174719 ↗ |
| Known as | HES 130/0.4 | “500 mL hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible...” NCT02393196 ↗1“6% hydroxyethyl starch (HES) 130/0.4 in a balanced electrolyte solution (Volulyte®)” NCT02034682 ↗ |
| Known as | HES 130/0.6 | “hydroxyethyl starch (HES 130/0.6)” NCT02502448 ↗1“hydroxyethyl starch (HES 130/0.6)” NCT06664320 ↗ |
| Known as | hydroxyethyl starch 130/0.4 | “250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.” NCT02337010 ↗ |
| Known as | Tetraspan | “hydroxyethyl starch (HES group, Tetraspan®) as CPB priming solution” PMID 29199540 ↗ Dec 2017 |
| Known as | Volulyte | “In the starch group, 6% hydroxyethyl starch 130/0.4 (Volulyte® ) was used as the primary fluid for volume resuscitation but was limited to 30 ml.kg-1 .” PMID 29150842 ↗ Nov 20172“6% hydroxyethyl starch (HES) 130/0.4 in a balanced electrolyte solution (Volulyte®)” NCT02034682 ↗ “Volulyte® (6% HES 130/0.4 in balanced solution)” NCT07410988 ↗ |
| Known as | Volulyte 6% | “Volulyte 6% (HES 130/0.4 in an isotonic composition)” NCT02034682 ↗ |
| Known as | voluven | “The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES, voluven) administered by gravity at a wide-open rate over a period of 15-30min before...” NCT03107598 ↗3“250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.” NCT02337010 ↗ “hydroxyethyl starch in sodium chloride injection Brand Name: Voluven” NCT05505708 ↗ “Hydroxyethyl Starch 130/0.4 (Voluven)” NCT00308126 ↗ |
| Modality | Other / unclassified | “hydroxyethyl starch (a synthetic colloid solution)” NCT00935168 ↗ |
| Route | Intravenous | “Intravenous fluid resuscitation with 6% Hydroxy-ethyl starch (130/0.4)” NCT00935168 ↗ |